Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/30/2003WO2003044018A1 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides
05/30/2003WO2003044017A1 Beta 3 adrenergic agonists
05/30/2003WO2003044016A1 3-SUBSTITUTED OXINDOLE β3 AGONISTS
05/30/2003WO2003044015A2 Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
05/30/2003WO2003044014A1 Indole-2-carboxamides as factor xa inhibitors
05/30/2003WO2003044010A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity
05/30/2003WO2003044009A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003044006A1 Substituted benzopyrans as selective estrogen receptor-beta agonists
05/30/2003WO2003044000A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043999A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043998A1 N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
05/30/2003WO2003043989A1 Hydrophilic (s)-amlodipine salts or their hydrates and pharmaceutical compositions
05/30/2003WO2003043988A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
05/30/2003WO2003043987A2 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
05/30/2003WO2003043985A1 Heterocyclic compounds and methods of use
05/30/2003WO2003043982A1 Derivatives of andrimide and moiramide b having antibacterial properties
05/30/2003WO2003043981A1 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
05/30/2003WO2003043980A1 Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
05/30/2003WO2003043975A1 Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease
05/30/2003WO2003043974A2 New pharmaceutical compounds
05/30/2003WO2003043972A2 Functional acylglycerides
05/30/2003WO2003043966A2 Clusianon isomers and use thereof
05/30/2003WO2003043905A2 Pharmaceutical product with an adsorbent
05/30/2003WO2003043672A1 Preparations appropriate for cartilage tissue formation
05/30/2003WO2003043668A2 Conditioning solution for contact lenses
05/30/2003WO2003043663A1 Compositions inhibiting rejection in organ transplantation and method of using the same
05/30/2003WO2003043662A1 Inclusion complex of taxol with 2-hydroxypropyl-beta-cyclodextrin
05/30/2003WO2003043661A1 Preparation compositions containing acid-unstable physiologically acitve compounds and process for producing the same
05/30/2003WO2003043660A2 Composition for stabilizing hyaluronic acid
05/30/2003WO2003043658A1 Anti-proliferative composition
05/30/2003WO2003043657A1 Topical delivery of codrugs
05/30/2003WO2003043656A1 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug
05/30/2003WO2003043655A1 Remedies for urinary frequency
05/30/2003WO2003043652A2 The use of leptin in fertility
05/30/2003WO2003043650A1 Use of fk506 and analogues for treating allergic diseases
05/30/2003WO2003043649A1 Removal promoters and inhibitor for apoptosis cells in vivo
05/30/2003WO2003043647A2 A plant extract active as an immunostimulating agent
05/30/2003WO2003043641A1 New pharmaceutical combinations prepared with alginates and biphosphonates in order to prevent gastroesophageal reflux during use of oral biphoshonates
05/30/2003WO2003043640A2 Treatment of major depressive disorder using glucocorticoid receptor antagonists
05/30/2003WO2003043639A2 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER
05/30/2003WO2003043638A1 Coated particulate cefuroxime axetil compositions
05/30/2003WO2003043637A1 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
05/30/2003WO2003043636A1 Nicotin-or isonicotin benzothiazole derivatives
05/30/2003WO2003043634A1 Benzothiazole derivatives as adenosine receptor ligands
05/30/2003WO2003043633A1 Use of an ascomycin for the treatment of blepharitis
05/30/2003WO2003043632A2 Use of bisindolmaleimide and gemcitabine for the treatment of cancer
05/30/2003WO2003043631A2 Method for identification of tumor targeting enzymes
05/30/2003WO2003043629A1 Medicine based on diethylaminoethanol derivatives and its use for the prevention and treatment of inflammatory and degenerative diseases
05/30/2003WO2003043628A1 Medicament for the treatment of viral skin and tumour diseases
05/30/2003WO2003043627A1 New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
05/30/2003WO2003043626A1 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
05/30/2003WO2003043625A1 2-aryl-propionic acids and pharmaceutical compositions containing them
05/30/2003WO2003043624A1 Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
05/30/2003WO2003043623A1 Antiviral, antibacterial pharmaceutical composition of cantharidic anhydride and method of preparation thereof
05/30/2003WO2003043622A1 Substituted bicyclo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients
05/30/2003WO2003043621A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003WO2003043620A1 A pharmaceutical composition for dermal application
05/30/2003WO2003043619A1 New use for the treatment of gastroesophageal reflux disease
05/30/2003WO2003043618A2 Amino diols useful in the treatment of alzheimer's disease
05/30/2003WO2003043617A1 Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
05/30/2003WO2003043616A2 Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
05/30/2003WO2003043615A2 Hypertonia treatment during the acute phase of a cerebrovascular accident
05/30/2003WO2003043614A2 Reversible proton pump inhibitors for the treatment of airway disorders
05/30/2003WO2003043613A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
05/30/2003WO2003043612A1 Micronized film-forming powder comprising an active substance
05/30/2003WO2003043610A2 A process for manufacture of a sustained release composition containing microbe
05/30/2003WO2003043608A1 Process for the preparation of tablets comprising s-adenosylmethionine
05/30/2003WO2003043607A1 A pharmaceutical composition for controlled release of a beta-lactam antibiotic
05/30/2003WO2003043606A1 Pharmaceutical formulation comprising bicalutamide
05/30/2003WO2003043604A1 Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid
05/30/2003WO2003043603A1 Particulate compositions for improving solubility of poorly soluble agents
05/30/2003WO2003043600A1 Water-soluble non-effervescent pharmaceutical compositions comprising non-steroidal anti-inflammatory drugs
05/30/2003WO2003043593A1 Use of cationic surfactant as antimicrobial activity enhancer in deodorants and oral care
05/30/2003WO2003043591A1 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation
05/30/2003WO2003043586A2 Compositions for sustained action product delivery
05/30/2003WO2003043584A2 Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003043581A2 Composition and method for modulating bar/fxr receptor activity
05/30/2003WO2003043579A2 Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
05/30/2003WO2003043577A2 Modulators of rho c activity
05/30/2003WO2003043576A2 Flowable osteogenic and chondrogenic compositions
05/30/2003WO2003043574A2 Pharmaceutical compositions in particulate form
05/30/2003WO2003043573A2 Xanthine oxidase inhibition
05/30/2003WO2003043572A2 Methods and compositions related to irm compounds and toll-like receptor pathways
05/30/2003WO2003043570A2 Formulations and methods for treatment or amelioration of inflammatory conditions
05/30/2003WO2003043569A2 Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
05/30/2003WO2003043438A1 Oilseed processing
05/30/2003WO2003043416A2 Methods and reagents for the control of infestations of parasites
05/30/2003WO2003032728A3 Methods for preventing or reversing asthma and compositions useful therefor
05/30/2003WO2003028697A3 Liposome loading with metal ions
05/30/2003WO2003026691A3 Use of hmgb1 for the activation of dendritic cells
05/30/2003WO2003024391A3 Treatment and prevention of mucositis in cancer patients
05/30/2003WO2003016917A3 Sodium channel regulators and modulators
05/30/2003WO2003013487A3 Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field
05/30/2003WO2003013478A3 Method of encapsulating an active substance
05/30/2003WO2003013442A3 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
05/30/2003WO2003010141A3 Hepatitis c virus polymerase inhibitors with a heterobicyclic structure
05/30/2003WO2003008448A3 Novel human proton-gated channels
05/30/2003WO2003007994A3 Thyroid therapeutic agents containing partial glycerides and dextrin
05/30/2003WO2003005998A3 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function
1 ... 5451 5452 5453 5454 5455 5456 5457 5458 5459 5460 5461 5462 5463 5464 5465 5466 5467 5468 5469 5470 5471 ... 7860